Apart from North America and Europe, instances of glioblastoma are prevalent in the Asia Pacific as well. To that end, Japan is one of the countries with a relative prevailing rate of glioblastoma owing to the presence of a high number of elderly individuals.
The disease is characterized as one of the most aggressive cancer which usually recurs periodically. Typically, a person suffering from glioblastoma survives for around one year, with a marginal survival rate of 3%-5% over five years.
Rising ageing population along with increasing awareness of novel therapies has added to the growth of the GBM market. The tumor continues to grow increasing with age, peaking between 75 to 84 years of age and then declines after 85 years.
In 2016, North America contributed to 39.2% of the global glioblastoma multiforme market share and is expected to witness steady growth over the forecast period. Substantial spending on the healthcare sector has resulted in the maturity of the treatment for the disease. U.S remained one of the leading GBM markets in the region.
Asia Pacific is expected to be the fastest-growing market over the forecast period and is expected to be valued over USD 270 million by 2024. High incidence rate of glioblastoma in Japan and China is expected to drive the market for its treatment solutions.
Companies are focusing on research and development in molecular biotechnology and gene therapy related to central nervous system and cancer. This advancement may provide an improvement in innovative possibilities for effective treatment of GBM over the forecast period.
Biologic products present a unique opportunity for focal treatment of GBM. Focal treatment techniques present an effective and feasible treatment option for those suffering from GBM. With biologic products, the focus is on treating the tumor at a cellular or molecular level. These factors together are expected to contribute to the growth of the GBM market over the next few years.
1.1. Market trends & movement
Chapter 2. The Case for Innovation in the Glioblastoma Multiforme Market
2.2. Key industry trends
2.3. Market drivers
2.4. Market restraints
2.5. Porters’ Five Forces analysis
2.7. GBM Prognosis and Prognostic Factors
2.8. Current Unmet Need in the GBM Market
2.9. Assessment of Pipeline Product Innovation
2.10. Signaling Network, Disease Causation and Innovation Alignment
2.11. First-in-Class Target Evaluation
Chapter 3. GBM Market Trends, By Region
3.1. Global GBM market movement, by region, 2016 & 2024
3.1.1. North America
188.8.131.52. Market estimates and forecast, 2014-2024
184.108.40.206. Market estimates and forecast, 2014-2024
3.1.3. Asia Pacific
220.127.116.11. Market estimates and forecast, 2014-2024
18.104.22.168. Market estimates and forecast, 2014-2024
Chapter 4. Competitive Landscape
4.1. Competitive landscape analysis, 2016
4.2. Strategic framework
4.2.1. Strategic consolidation
4.3. Potential customer base concentration
4.4. Company market positioning
4.5. Company profiles
4.5.1. Genentech, Inc.
22.214.171.124. Company overview
126.96.36.199. Product benchmarking
188.8.131.52. Financial performance
184.108.40.206. Recent initiatives
4.5.2. Bristol-Myers Squibb
220.127.116.11. Company overview
18.104.22.168. Product benchmarking
22.214.171.124. Financial performance
126.96.36.199. Recent initiatives
4.5.3. Emcure Pharmaceuticals Limited
188.8.131.52. Company overview
184.108.40.206. Product benchmarking
220.127.116.11. Financial performance
18.104.22.168. Recent initiatives
4.5.4. Arbor Pharmaceuticals, LLC
22.214.171.124. Company overview
126.96.36.199. Product benchmarking
188.8.131.52. Financial performance
184.108.40.206. Recent initiatives
4.5.5. F. Hoffmann-La Roche AG
220.127.116.11. Company overview
18.104.22.168. Product benchmarking
22.214.171.124. Financial performance
126.96.36.199. Recent initiatives
4.5.6. Merck & Co., Inc.
188.8.131.52. Company overview
184.108.40.206. Product benchmarking
220.127.116.11. Financial performance
18.104.22.168. Recent initiatives
4.5.7. Sun Pharmaceutical Industries, Ltd.
22.214.171.124. Company overview
126.96.36.199. Product benchmarking
188.8.131.52. Financial performance
184.108.40.206. Recent initiatives
4.5.8. Teva Pharmaceutical Industries
220.127.116.11. Company overview
18.104.22.168. Product benchmarking
22.214.171.124. Financial performance
126.96.36.199. Recent initiatives
4.5.9. Sigma-Tau Pharmaceuticals, Inc.
188.8.131.52. Company overview
184.108.40.206. Product benchmarking
220.127.116.11. Financial performance
18.104.22.168. Recent initiatives
22.214.171.124. Company overview
126.96.36.199. Product benchmarking
188.8.131.52. Financial performance
184.108.40.206. Recent initiatives
4.6. List of vendors
Chapter 5. Methodology and Scope
5.1. Research methodology
5.2. Research Scope & Assumptions
5.3. List of data sources
*Full List of Tables & Figures Available on Enquiry.
- Genentech, Inc.
- Bristol-Myers Squibb
- Emcure Pharmaceuticals Limited
- Arbor Pharmaceuticals, LLC
- F. Hoffmann-La Roche AG
- Merck & Co., Inc.
- Sun Pharmaceutical Industries, Ltd.
- Teva Pharmaceutical Industries
- Sigma-Tau Pharmaceuticals, Inc.